Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

7966.1;5 LSPP-LS

Titre du projet

Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease

Titre du projet anglais

Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease
Résumé des résultats (Abstract) (Anglais)	The objective of this collaboration is the preclinical development of a humanized antibody, in particular a humanized single-chain (scFv) antibody fragment for the treatment and prevention of Alzheimer¿s Disease. For this reason the mechanism of action of various antibody fragments as well as pharmacokinetic and pharmacodynamic properties of an existing lead antibody (ESBA212), the latter resulting from a scientific collaboration between Prof. Nitsch and ESBATech, shall be characterized in detail in vivo in animal models of passive immunization of Alzheimer¿s Disease.

Catégorie

Texte

Description succincte
(Anglais)

Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease

Résumé des résultats (Abstract)
(Anglais)

The objective of this collaboration is the preclinical development of a humanized antibody, in particular a humanized single-chain (scFv) antibody fragment for the treatment and prevention of Alzheimer¿s Disease. For this reason the mechanism of action of various antibody fragments as well as pharmacokinetic and pharmacodynamic properties of an existing lead antibody (ESBA212), the latter resulting from a scientific collaboration between Prof. Nitsch and ESBATech, shall be characterized in detail in vivo in animal models of passive immunization of Alzheimer¿s Disease.